Metformin: an old but still the best treatment for type 2 diabetes
Open Access
- 15 February 2013
- journal article
- Published by Springer Science and Business Media LLC in Diabetology & Metabolic Syndrome
- Vol. 5 (1), 6-15
- https://doi.org/10.1186/1758-5996-5-6
Abstract
The management of T2DM requires aggressive treatment to achieve glycemic and cardiovascular risk factor goals. In this setting, metformin, an old and widely accepted first line agent, stands out not only for its antihyperglycemic properties but also for its effects beyond glycemic control such as improvements in endothelial dysfunction, hemostasis and oxidative stress, insulin resistance, lipid profiles, and fat redistribution. These properties may have contributed to the decrease of adverse cardiovascular outcomes otherwise not attributable to metformin’s mere antihyperglycemic effects. Several other classes of oral antidiabetic agents have been recently launched, introducing the need to evaluate the role of metformin as initial therapy and in combination with these newer drugs. There is increasing evidence from in vivo and in vitro studies supporting its anti-proliferative role in cancer and possibly a neuroprotective effect. Metformin’s negligible risk of hypoglycemia in monotherapy and few drug interactions of clinical relevance give this drug a high safety profile. The tolerability of metformin may be improved by using an appropiate dose titration, starting with low doses, so that side-effects can be minimized or by switching to an extended release form. We reviewed the role of metformin in the treatment of patients with type 2 diabetes and describe the additional benefits beyond its glycemic effect. We also discuss its potential role for a variety of insulin resistant and pre-diabetic states, obesity, metabolic abnormalities associated with HIV disease, gestational diabetes, cancer, and neuroprotection.Keywords
This publication has 157 references indexed in Scilit:
- Metformin, Independent of AMPK, Inhibits mTORC1 in a Rag GTPase-Dependent MannerCell Metabolism, 2010
- Metformin Therapy and Outcomes in Patients With Advanced Systolic Heart Failure and DiabetesJournal of Cardiac Failure, 2010
- 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes StudyThe Lancet, 2009
- Antidiabetic Therapies Affect Risk of Pancreatic CancerGastroenterology, 2009
- Status of PI3K inhibition and biomarker development in cancer therapeuticsAnnals of Oncology, 2009
- Enhancing CD8 T-cell memory by modulating fatty acid metabolismNature, 2009
- Antidiabetic drug metformin (Glucophage R ) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcriptionProceedings of the National Academy of Sciences of the United States of America, 2009
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesThe New England Journal of Medicine, 2008
- Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated?BMJ, 2007
- Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysisBMJ, 2007